drugset

drugset / Trial / NCT06941129

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

NCT06941129 ↗

Phase 1 Recruiting 12 enrolled Institute of Hematology & Blood Diseases Hospital, China Shanghai Xiniao Biotech Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Timeline

Start: 2025-02-11
Primary completion: 2028-02-18
Completion: 2028-03-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UCAR T-cell	Cell therapy	—	Intravenous

Indications